Brief: Oncolytics Provides Update On Pancreatic Cancer Program For Pelareorep

Oncolytics Biotech

09/11/2023 12:21

Nov 9 (Reuters) - Oncolytics Biotech Inc  ONC.TO :
    * ONCOLYTICS PROVIDES UPDATE ON PANCREATIC CANCER PROGRAM
FOR
PELAREOREP
    * ONCOLYTICS BIOTECH INC - UPDATED PLAN FOLLOWS PANCAN'S
STRATEGIC
RE-EVALUATION OF PRECISION PROMISE(SM) PROGRAM
    * ONCOLYTICS BIOTECH INC - PANCAN US$5 MILLION GRANT
PROVIDES
SUPPORT FOR NEW GOBLET MFOLFIRINOX ARM TO PROCEED AS PLANNED
    * ONCOLYTICS BIOTECH - TO CONDUCT ADAPTIVE PHASE 3 PROGRAM
OF
PELAREOREP, GEMCITABINE, NAB-PACLITAXEL, ATEZOLIZUMAB, SIMILAR
TO PRECISION PROMISE STUDY
    * ONCOLYTICS BIOTECH INC - PLANS TO PROVIDE A FURTHER UPDATE
ON
DESIGN OF PHASE 3 TRIAL IN H1 2024
    * ONCOLYTICS BIOTECH INC - REMAINS STEADFAST IN ITS
COMMITMENT TO
INITIATE PHASE 3 PROGRAM FOR PELAREOREP, STARTING IN PDAC, IN
2024
    * ONCOLYTICS BIOTECH INC - EXPECT TO INITIATE ENROLLMENT OF
FIRST
PATIENT IN MID-2024

Source text for Eikon:  ID:nPn7tjqy1a 
Further company coverage:  ONC.TO 

 ((Reuters.Briefs@thomsonreuters.com;))